Posted by Michael Wonder on 08 Aug 2018
ABPI response: MHRA guidance on Brexit Implementation
6 August 2018 - The MHRA has published technical guidance on what a Brexit implementation period means for the life sciences sector, once finalised as part of the Withdrawal Agreement.
In response, Dr Sheuli Porkess, Deputy Chief Scientific Officer for the ABPI said:
“Pharmaceutical companies need as much clarity as possible so they can continue to supply medicines to patients as the UK leaves the EU. Today’s guidance from Government is welcome, as is the reiteration of the UK’s preference for close cooperation with the EU across all aspects of medicines regulation.
